umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
The role of hormones and hormonal treatments in premenstrual syndrome
Umeå University, Faculty of Medicine, Department of Clinical Sciences, Obstetrics and Gynaecology.
Umeå University, Faculty of Medicine, Department of Clinical Sciences, Obstetrics and Gynaecology.
Umeå University, Faculty of Medicine, Department of Clinical Sciences, Obstetrics and Gynaecology.
Umeå University, Faculty of Medicine, Department of Clinical Sciences, Obstetrics and Gynaecology.
Show others and affiliations
2003 (English)In: CNS Drugs, ISSN 1172-7047, E-ISSN 1179-1934, Vol. 17, no 5, 325-342 p.Article in journal (Refereed) Published
Abstract [en]

Premenstrual syndrome (PMS) is a menstrual cycle-linked condition with both mental and physical symptoms. Most women of fertile age experience cyclical changes but consider them normal and not requiring treatment. Up to 30% of women feel a need for treatment. The aetiology is still unclear, but sex steroids produced by the corpus luteum of the ovary are thought to be symptom provoking, as the cyclicity disappears in anovulatory cycles when a corpus luteum is not formed. Progestogens and progesterone together with estrogen are able to induce similar symptoms as seen in PMS. Symptom severity is sensitive to the dosage of estrogen. The response systems within the brain known to be involved in PMS symptoms are the serotonin and GABA systems. Progesterone metabolites, especially allopregnanolone, are neuroactive, acting via the GABA system in the brain. Allopregnanolone has similar effects as benzodiazepines, barbiturates and alcohol; all these substances are known to induce adverse mood effects at low dosages in humans and animals. SSRIs and substances inhibiting ovulation, such as gonadotrophin-releasing hormone (GnRH) agonists, have proven to be effective treatments. To avoid adverse effects when high dosages of GnRH agonists are used, add-back hormone replacement therapy is recommended. Spironolactone also has a beneficial effect, although not as much as SSRIs and GnRH agonists.

Place, publisher, year, edition, pages
2003. Vol. 17, no 5, 325-342 p.
Keyword [en]
Premenstrual syndrome, Serotonin reuptake inhibitors, therapeutic use, Gonadotropin releasing hormone agonists, therapeutic use, Surgery, Oral contraceptives, therapeutic use, Spironolactone, therapeutic use, Progesterone, therapeutic use, Hormones, therapeutic use
Identifiers
URN: urn:nbn:se:umu:diva-37054PubMedID: 12665391OAI: oai:DiVA.org:umu-37054DiVA: diva2:357623
Available from: 2010-10-19 Created: 2010-10-19 Last updated: 2017-12-12Bibliographically approved

Open Access in DiVA

No full text

PubMed

Authority records BETA

Bäckström, TorbjörnAndreen, LottaBjörn, IngerJohansson, Inga-MajNyberg, SigridWahlström, GöranWang, Mingde

Search in DiVA

By author/editor
Bäckström, TorbjörnAndreen, LottaBjörn, IngerJohansson, Inga-MajNyberg, SigridWahlström, GöranWang, Mingde
By organisation
Obstetrics and Gynaecology
In the same journal
CNS Drugs

Search outside of DiVA

GoogleGoogle Scholar

pubmed
urn-nbn

Altmetric score

pubmed
urn-nbn
Total: 156 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf